MarketScreener Homepage > Equities > Nasdaq > Inovio Pharmaceuticals, Inc. INO

Report

Delayed Nasdaq - 01/15 04:00:00 pm
9.66	USD		+3.10%

01/06

INOVIO PHARMACEUTICALS : Reports Positive Efficacy in Phase 2 Trial of VGX-3100 to Treat Vulvar Dysplasia Caused by HPV

01/06

INOVIO PHARMACEUTICALS : VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

01/04

INOVIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

01/11/2021	01/12/2021	01/13/2021	01/14/2021	01/15/2021	Date
9.085(c)	9.1(c)	9.225(c)	9.37(c)	9.66(c)	Last
7 000 605	5 347 783	7 116 527	5 409 962	19 984 455	Volume
-1.46%	+0.17%	+1.37%	+1.57%	+3.09%	Change

More quotes

Financials (USD)

Sales 2020	4,05 M - -
Net income 2020	-181 M - -
Net Debt 2020	- - -
P/E ratio 2020	-8,20x
Yield 2020	-

Sales 2021	86,4 M - -
Net income 2021	-156 M - -
Net Debt 2021	- - -
P/E ratio 2021	-10,8x
Yield 2021	-

Capitalization	1 636 M 1 636 M -
Capi. / Sales 2020	404x
Capi. / Sales 2021	18,9x
Nbr of Employees	190
Free-Float	97,8%

More Financials

Company

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target...

Sector

Biotechnology & Medical Research

Calendar

03/17

Earnings Release

More about the company

Notations Surperformance© of Inovio Pharmaceuticals, Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about INOVIO PHARMACEUTICALS, INC.

01/06	INOVIO PHARMACEUTICALS : Reports Positive Efficacy in Phase 2 Trial of VGX-3100 ..	MT
01/06	INOVIO PHARMACEUTICALS : VGX-3100 Demonstrates Positive Phase 2 Efficacy In Trea..	PR
01/04	INOVIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regul..	AQ
01/04	Inovio expects to begin late-stage COVID-19 vaccine study in second quarter	RE
01/04	INOVIO PHARMACEUTICALS : Partners With Advaccine to Commercialize COVID-19 DNA V..	MT
01/04	INOVIO PHARMACEUTICALS : partners with Advaccine to commercialize COVID-19 vacci..	RE
01/04	INOVIO PHARMACEUTICALS : and Advaccine Announce Exclusive Partnership To Commerc..	PR
2020	SECTOR UPDATE : Health Care Stocks Hang On For Modest Gains	MT
2020	INOVIO PHARMACEUTICALS' : Early Stage US Study Shows Potential of COVID-19 Vacci..	MT
2020	INOVIO PHARMACEUTICALS : Announces Publication of Phase 1 Data from its COVID-19..	PR
2020	INOVIO PHARMACEUTICALS : Wins $38 Million Grant to Develop Antibody Technologies..	MT
2020	INOVIO PHARMACEUTICALS : to Develop DNA-encoded Monoclonal Antibody (dMAb®) Cand..	PR
2020	Inovio Begins Dosing in Trial of COVID-19 DNA Vaccine Candidate in China	MT
2020	INOVIO PHARMACEUTICALS : and Advaccine Announce First Dosing of Subject in Phase..	PR
2020	Inovio Pharmaceuticals Reports Positive Efficacy Results From Phase 2 Trial o..	MT

More news

News in other languages on INOVIO PHARMACEUTICALS, INC.

2020	WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2020	Wall Street, lestée par la tech, finit dans le rouge
2020	BioNTech treibt Corona-Impfstoffprojekt nach positiven Daten voran
2020	WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2020	WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street

More news

Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.

2020	Roth Capital Downgrades Inovio Pharmaceuticals Back to Sell From Neutral; Pri..	MT
2020	Roth Capital Upgrades Inovio Pharmaceuticals to Neutral From Sell; Price Targ..	MT
2020	RBC Capital Adjusts Inovio Pharmaceuticals PT to $11 From $12, Maintains Sect..	MT

More recommendations

Stock Trading Strategies

	INOVIO PHARMACEUTICALS, INC. - 2020
Close to a key resistance level

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

Inovio Pharmaceuticals : Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses